The glucocorticoid receptor is the primary target for synthesized corticosteroids and it is unclear if activation of the glucocorticoid receptor is linked to increased or reduced metastatic potential in colorectal cancer (36–40). This evidence concerns the gene NR3C1 and colorectal cancer.